In Brief: Activated Cell Therapy, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Activated Cell Therapy, Inc.: Receives 510(k) clearance from FDA for its "patented cell processing devices used for cell isolation and enrichment," the Mountain View, California firm announces. Consisting of a series of buoyant density solutions and centrifugal devices, ACT's technology "allows the efficient recovery and preparation of important cells, such as stem cells and dendritic cells, from peripheral blood, bone marrow, or cord blood." ACT has clinical studies ongoing to treat patients with breast cancer, leukemia and lymphoma using stem cells from bone marrow and peripheral blood...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.